HEPA on OTC

Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals, Inc. is an American pharmaceutical preparations company based in Red Bank.2 Its shares trade on OTC under the symbol HEPA.2

Price unavailable

Last updated Oct 20, 2026.

Overview

Compare with another stock.

  • TickerHEPA on OTC2
  • IndustryPharmaceutical Preparations2
  • HeadquartersNew York, United States2
  • Incorporated inDE3
  • Business address34 Shrewsbury Ave., Suite 1D, Red Bank, Nj 077013
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI5493004WF12U6NOV8U202
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O National Registered Agents, Inc., 19801 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 53351172

See how the biggest companies compare on our leaderboards

U.S. and foreign governments periodically propose and pass legislation designed to reduce the cost of healthcare and pharmaceutical products.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-672.0%Return on equity5
-$40.9MFree cash flow6

Financial statements

Revenue789$0 in 2023
02020: $0$020202021: $0$020212022: $0$020222023: $0$02023
Operating income107896-$48.4M in 2023+524% since 2019
-$60.0M-$40.0M-$20.0M02019: -$7.8M-$7.8M20192020: -$20.1M-$20.1M2020+159%2021: -$30.4M-$30.4M2021+51%2022: -$45.5M-$45.5M2022+50%2023: -$48.4M-$48.4M2023+7%
Net income107896-$48.9M in 2023+595% since 2019
-$60.0M-$40.0M-$20.0M02019: -$7.0M-$7.0M20192020: -$20.4M-$20.4M2020+189%2021: -$32.7M-$32.7M2021+61%2022: -$42.2M-$42.2M2022+29%2023: -$48.9M-$48.9M2023+16%

Every line of the income statement as filed: the last 2 fiscal years, latest first.5

Period ending2025-12-312024-12-31
Research and development$445.5K$11.8M
General and administrative$3.3M$7.5M
Asset impairment loss$402.7K
Total operating expenses$4.2M$19.3M
Loss from operations-$4.2M-$19.3M
Interest expense, net-$24.4K-$1.2M
Write-off related party note receivable-$600.0K
Change in fair value of contingent consideration and derivative financial instruments-$4.1M$7.6M
Inducement expense-$2.6M
Loss before income taxes-$8.3M-$16.2M
Income tax benefit (expense)$3.0M
Net loss-$8.3M-$13.2M
Weighted-average common shares outstanding basic9.4M shares122.9K shares
Weighted-average common shares outstanding diluted9.4M shares122.9K shares
Net loss per common share basic-$0.88-$107.35
Net loss per common share diluted-$0.88-$107.35

Compare Hepion Pharmaceuticals, Inc. with another company

Corporate structure

Hepion Pharmaceuticals, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Hepion Pharmaceuticals, Inc.

  • KI Holdings, Ltd. Filed SCHEDULE 13D/A on Hepion Pharmaceuticals, Inc., latest Sep 16, 2026
  • Kenneth Rickel Filed SCHEDULE 13G on Hepion Pharmaceuticals, Inc., latest Sep 15, 2026
  • Gary S. Stetz Filed SCHEDULE 13D on Hepion Pharmaceuticals, Inc., latest Aug 20, 2026
  • Sireesh Appajosyula Filed SCHEDULE 13D on Hepion Pharmaceuticals, Inc., latest Aug 20, 2026
  • Vincent S. Lopriore Filed SCHEDULE 13D/A on Hepion Pharmaceuticals, Inc., latest Aug 20, 2026 (2 filings since May 1, 2026)
  • Black Global 5 LLC Filed SCHEDULE 13D on Hepion Pharmaceuticals, Inc., latest Aug 7, 2026
  • Anson Funds Management LP Filed SCHEDULE 13G/A on Hepion Pharmaceuticals, Inc., latest Aug 14, 2025 (2 filings since May 15, 2025)
  • S.H.N. Financial Investments Ltd. Filed SCHEDULE 13G/A on Hepion Pharmaceuticals, Inc., latest Aug 14, 2025 (2 filings since Jan 27, 2025)
  • BIGGER CAPITAL FUND L P Filed SCHEDULE 13G on Hepion Pharmaceuticals, Inc., latest Jan 24, 2025
  • ARMISTICE CAPITAL, LLC Filed SC 13G/A on Hepion Pharmaceuticals, Inc., latest Nov 14, 2024 (2 filings since Feb 14, 2024)
  • Altium Capital Management LLC Filed SC 13G/A on Hepion Pharmaceuticals, Inc., latest Feb 14, 2022
  • VANGUARD GROUP INC Filed SC 13G/A on Hepion Pharmaceuticals, Inc., latest Feb 10, 2022
  • Hepion Pharmaceuticals, Inc. New York, New York, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Hepion Pharmaceuticals, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Accumulated depreciation$420.7K6 Dec 31, 2024$379.5K6 Dec 31, 2023+10.9%
Operating-lease assets (leased space)$05 Dec 31, 2025$212.9K6 Dec 31, 2023−100.0%

Properties, in its own words

Our corporate headquarters are located at 55 Madison Ave, Suite 400- PMB #462, Morristown, New Jersey, 07960.

Item 2 of the 10-K filed Mar 12, 2026.4

Leadership

Who has led Hepion Pharmaceuticals, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Gary S. Jacob2013–2014
  2. James Sapirstein2014–2018
  3. Robert T. Foster2019–2023
  4. Gary S. Stetz2026–now

Chair

  1. John P. Brancaccio2024
  2. Vincent S. Lopriore2026–now

President

  1. Gary S. Jacob2013–2014

Chief financial officer

  1. Bernard Denoyer2013–2014
  2. William Karl Hornung2014–2015
  3. John T. Cavan2016–2021

Chief operating officer

  1. Sireesh Appajosyula2026–now
201520202025
Board members and other officers (21)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Chief Medical OfficerTodd Hobbs named Nov 15, 202241
  • DirectorDania Fisher named Aug 5, 202642
  • DirectorPetrus P. Wijngaard named Nov 15, 2022 to Oct 3, 202343
  • DirectorGary S. Jacobs named Nov 15, 202241

Former names

  • ContraVir Pharmaceuticals, Inc.Aug 8, 2013 to Jul 23, 20193

Timeline

  1. Oct 9, 20268-K Entered a material agreement; Completed an acquisition or sale; Unregistered sale of shares44
  2. Oct 2, 20268-K Bylaws or fiscal year changed45
  3. Sep 28, 20268-K Change of auditor46
  4. Sep 8, 20268-K Entered a material agreement; New debt or obligation; Unregistered sale of shares47
  5. Aug 27, 20268-K Entered a material agreement; Unregistered sale of shares48
  6. Aug 20, 20268-K Executive or director change49
  7. Aug 4, 20268-K Entered a material agreement; Unregistered sale of shares50
  8. Jul 2, 20268-K Executive or director change51
  9. Jun 17, 20268-K Shareholder vote52
  10. Apr 22, 20268-K Entered a material agreement; Unregistered sale of shares53
  11. Apr 14, 20268-K Entered a material agreement; Executive or director change54
  12. Mar 18, 2026New chief executive Gary S. Stetz becomes CEO14
  13. Mar 18, 20268-K Executive or director change55
  14. Jul 25, 2019New chief executive Robert T. Foster becomes CEO15
  15. Mar 20, 2014New chief executive James Sapirstein becomes CEO16
  16. Oct 7, 2013New chief executive Gary S. Jacob becomes CEO17
  17. May 15, 2013Founded Hepion Pharmaceuticals, Inc. is founded2

Filings

217 filings to the SEC since October 2021: 7 annual reports, 15 quarterly reports, 62 major events, 40 insider forms, 18 large holders, 5 private raises, 70 other. The latest 20:

  1. Oct 14, 2026S-8 EDGAR
  2. Oct 9, 20268-K EDGAR
  3. Oct 2, 20264 EDGAR
  4. Oct 2, 20268-K EDGAR
  5. Sep 28, 20268-K EDGAR
  6. Sep 16, 20263 EDGAR
  7. Sep 16, 2026SCHEDULE 13D/A EDGAR
  8. Sep 15, 2026SCHEDULE 13G EDGAR
  9. Sep 14, 20264 EDGAR
  10. Sep 10, 2026DEF 14C EDGAR
  11. Sep 10, 20264 EDGAR
  12. Sep 8, 20268-K EDGAR
  13. Aug 31, 2026PRE 14C EDGAR
  14. Aug 27, 20268-K EDGAR
  15. Aug 21, 20264 EDGAR
  16. Aug 21, 20264 EDGAR
  17. Aug 21, 20264 EDGAR
  18. Aug 21, 20264 EDGAR
  19. Aug 21, 20264 EDGAR
  20. Aug 21, 20264 EDGAR

The 217 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

15 open-market trades by officers, directors and large owners since October 2021: 15 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 3, 2026Stetz Gary S. IIDirectorBuy500,000$0.05$25.0KForm 4
Aug 3, 2026Stetz Gary S.Interim CEOBuy2,000,000$0.05$100.0KForm 4
Aug 3, 2026Purcell Michael J.DirectorBuy2,000,000$0.05$100.0KForm 4
Aug 3, 2026Appajosyula SireeshChief Operating OfficerBuy2,000,000$0.05$100.0KForm 4
Aug 3, 2026LoPriore Vincent SExecutive ChairmanBuy10,000,000$0.05$500.0KForm 4
Apr 21, 2026Purcell Michael J.DirectorBuy1,250,000$0.04$50.0KForm 4
Apr 21, 2026LoPriore Vincent SExecutive ChairmanBuy6,250,000$0.04$250.0KForm 4
Apr 21, 2026Appajosyula SireeshChief Operating OfficerBuy1,250,000$0.04$50.0KForm 4
Apr 21, 2026Stetz Gary S.Interim CEOBuy1,250,000$0.04$50.0KForm 4
Nov 27, 2023Wijngaard PeterDirectorBuy2,500$3.05$7.6KForm 4
Nov 24, 2023Wijngaard PeterDirectorBuy2,500$3.09$7.7KForm 4
Sep 19, 2023Wijngaard PeterDirectorBuy1,000$5.64$5.6KForm 4
Sep 18, 2023Foster Robert TCEO and DirectorBuy1,600$5.60$9.0KForm 4
Sep 15, 2023Wijngaard PeterDirectorBuy2,000$5.60$11.2KForm 4
Sep 15, 2023Foster Robert TCEO and DirectorBuy1,600$5.40$8.6KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025John Brancaccio$232.5K$232.5K70
2025Former ChiefExecutive Officer$198.0K$198.0K70
2024Former Interim ChiefExecutive Officer and Chief Financial Officer$313.9K$502.3K70

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Jul 31, 2026Raised $3.1 million in a private offering of equity Form D: 33 investors so far Form D
  2. Apr 21, 2026Raised $700,000 in a private offering of equity Form D: 11 investors so far Form D
  3. Jul 19, 2024Raised $2.9 million in a private offering of securities Form D: 7 investors so far Form D
  4. Sep 28, 2023Raised $5 million in a private offering of equity Form D: 1 investor so far Form D
  5. Nov 4, 2022Raised $20 million in a private offering of equity Form D: 8 investors so far Form D

SEC filer profile

How Hepion Pharmaceuticals, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARHepion Pharmaceuticals, Inc.1
  • CIK0001583771
  • Employer ID (EIN)46-27838064
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; a shell company4
  • Incorporated inDelaware4
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address34 Shrewsbury Ave., Suite 1D, Red Bank, NJ 077011
  • Phone732-902-40001
  • Shares outstanding90,219,317 as of Aug 10, 202612
  • Public float$900.0K as of Jun 30, 20254
  • AuditorGrassi & Co., CPAs, P.C, Jericho, New York PCAOB ID 606; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceAug 8, 20131
  • Filings712 in all: 8-K (261), 4 (120), 10-Q (39), 3 (29), CORRESP (22), DEFA14A (18), SC 13G (18), UPLOAD (18)1
    All 50 form types

    DEF 14A (16), SC 13G/A (14), 10-K (12), 424B5 (12), S-1/A (11), EFFECT (10), D (9), PRE 14A (9), S-1 (8), S-8 (7), 10-12G/A (5), 10-K/A (5), 424B4 (5), 425 (4), ARS (4), FWP (4), NT 10-K (4), SCHEDULE 13D (4), SCHEDULE 13G (4), 8-K/A (3), CT ORDER (3), NT 10-Q (3), PRER14A (3), S-3 (3), 424B3 (2), RW (2), S-1MEF (2), S-3/A (2), SC 13D (2), SCHEDULE 13D/A (2), SCHEDULE 13G/A (2), 10-12G (1), 10-KT (1), 10-Q/A (1), 25-NSE (1), 8-A12B (1), ARS/A (1), CERTNAS (1), DEF 14C (1), PRE 14C (1), RW WD (1), SC 13D/A (1)

  • Latest filingsAnnual report (10-K) Mar 12, 2026
    Quarterly report (10-Q) Aug 13, 2026
    Proxy statement (DEF 14A) Apr 28, 2026
    Latest 8-K (8-K) Oct 9, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, par value $0.0001 per shareHEPA

From the cover page of the 10-K filed Mar 12, 2026 (Section 12(b) of the Exchange Act).4

Risk factors and legal proceedings

The risks Hepion Pharmaceuticals, Inc. names in Item 1A of its 10-K filed Mar 12, 2026: 60 risks under these headings, as written.4

  • Risks Related to Our Business
  • We have incurred losses since inception, anticipate that we will incur continued losses for the foreseeable future indicating the possibility that we may not be able to operate in the future.
  • We expect future product candidates to be in the early stages of development and commercial viability remains subject to the successful outcome of current and future preclinical studies, clinical trials, regulatory approvals and the risks generally inherent in the development of a pharmaceutical product candidate. If we are unable to successfully advance or develop our product candidates, our business will be materially harmed.
  • If the results of preclinical studies or clinical trials for our product candidates, including those that are subject to existing or future license or collaboration agreements, are unfavorable or delayed, we could be delayed or precluded from the further development or commercialization of our product candidate, which could materially harm our business.
  • If third party vendors upon whom we intend to rely on to conduct our preclinical studies or clinical trials do not perform or fail to comply with strict regulations, these studies or trials of our product candidates may be delayed, terminated, or fail, or we could incur significant additional expenses, which could materially harm our business.
  • We have limited capacity for recruiting and managing clinical trials, which could impair our timing to initiate or complete clinical trials of our product candidates and materially harm our business.
  • We, and our collaborators, must comply with extensive government regulations in order to advance our product candidates through the development process and ultimately obtain and maintain marketing approval for our products in the U.S. and abroad.
  • We will require substantial additional funding which may not be available to us on acceptable terms, or at all. If we fail to raise the necessary additional capital, we may be unable to complete the development and commercialization of our product candidates or continue our development programs.
  • The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidate, our business will be substantially harmed.
  • We may be required to suspend or discontinue clinical trials due to unexpected side effects or other safety risks that could preclude approval of our product candidates.
  • If we fail to comply with healthcare regulations, we could face substantial enforcement actions, including civil and criminal penalties and our business, operations and financial condition could be adversely affected.
  • If we are unable to satisfy regulatory requirements, we may not be able to commercialize our product candidates.
The other 49 risks
  • We currently have no sales and marketing organization. If we are unable to establish a direct sales force in the United States to promote our products, the commercial opportunity for our products may be diminished.
  • We may need others to market and commercialize our product candidate in international markets.
  • We may not be able to manufacture our product candidates in commercial quantities, which would prevent us from commercializing our product candidates.
  • Materials necessary to manufacture our product candidates may not be available on commercially reasonable terms, or at all, which may delay the development and commercialization of our product candidates.
  • Our product candidates, if approved for sale, may not gain acceptance among physicians, patients and the medical community, thereby limiting our potential to generate revenues.
  • Guidelines and recommendations published by various organizations can impact the use of our product.
  • If third-party contract manufacturers upon whom we intend to rely on to formulate and manufacture our product candidates do not perform, fail to manufacture according to our specifications or fail to comply with strict regulations, our preclinical studies or clinical trials could be adversely affected and the development of our product candidates could be delayed or terminated or we could incur significant additional expenses.
  • In the event that we need to change our third-party contract manufacturers, our preclinical studies, clinical trials or the commercialization of our product candidate could be delayed, adversely affected or terminated, or such a change may result in significantly higher costs.
  • If a product liability claim is successfully brought against us for uninsured liabilities, or such claim exceeds our insurance coverage, we could be forced to pay substantial damage awards that could materially harm our business.
  • If our use of hazardous materials results in contamination or injury, we could suffer significant financial loss.
  • Our operations could be disrupted if our information systems fail, if we are unsuccessful in implementing necessary upgrades or if we are subject to cyber-attacks.
  • Business disruptions could seriously harm future revenue and financial condition and increase our costs and expenses.
  • Risks Relating to the Commercialization of our Product Candidate.
  • We may delay or terminate the development of our product candidates at any time if we believe the perceived market or commercial opportunity does not justify further investment, which could materially harm our business.
  • If we fail to enter into or maintain collaborations or other sales, marketing and distribution arrangements with third parties to commercialize our product candidates, or otherwise fail to establish marketing and sales capabilities, we may not be able to successfully commercialize our products.
  • If government and third-party payers fail to provide adequate reimbursement or coverage for our products or those we develop through collaborations, our revenues and potential for profitability will be harmed.
  • If any product candidate that we develop independently or through collaborations is approved but does not gain meaningful acceptance in its intended market, we are not likely to generate significant revenues or become profitable.
  • Even if we or a collaborator achieve market acceptance for our product, we may experience downward pricing pressure on the price of our product due to social or political pressure to lower the cost of drugs, which would reduce our revenue and future profitability.
  • We may be unable to successfully develop a product candidate that is the subject of collaboration if our collaborator does not perform, terminates our agreement, or delays the development of our product candidate.
  • Risks Related to Our Intellectual Property
  • If we are unable to adequately protect or expand our intellectual property related to our future product candidates, our business prospects could be harmed.
  • If a third party claims we are infringing on its intellectual property rights, we could incur significant expenses, or be prevented from further developing or commercializing our product candidates.
  • Confidentiality agreements with employees and others may not adequately prevent disclosure of trade secrets and other proprietary information and may not adequately protect our intellectual property.
  • Our failure to successfully discover, acquire, develop and market additional product candidates or approved products would impair our ability to grow.
  • Risks Related to Government Regulation
  • We conduct our business in a heavily regulated industry, and changes in regulations or violations of regulations may, directly or indirectly, reduce our revenue, adversely affect our results of operations and financial condition and harm our business.
  • The insurance coverage and reimbursement status of newly approved products, in a new category of diagnostics and therapeutics, is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for current or future products could limit our ability, and that of our collaborators, to fully commercialize our products and decrease our ability to generate revenue.
  • Changes in law relating to health insurance coverage and payment may adversely affect our business.
  • Inadequate funding for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.
  • We must maintain compliance with marketing authorization requirements of the FDA and equivalent foreign and state regulatory authorities for our products and services whose sale is subject to their authority and failure to maintain compliance with FDA requirements may prevent or delay the marketing of our products and services.
  • For each product we are developing that requires FDA premarket review or equivalent regulatory approval, the FDA or other regulatory authority may not grant clearance, authorization or premarket approval and failure to obtain necessary approvals for our future products and services would adversely affect our ability to grow our business.
  • Modifications to our products with FDA clearance may require new FDA clearances, authorizations or approvals, or may require us to cease marketing or recall the modified clinical diagnostic products or future clinical products until clearances are obtained.
  • Our employees, consultants and collaborators may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.
  • Future Medicare payment rates are uncertain.
  • Our products, and those jointly developed with our collaborators, may in the future be subject to product or service recalls. A recall of products or services, either voluntarily or at the direction of the FDA or another governmental authority, or the discovery of serious safety issues with our or our collaborators’ products or services, could have a significant adverse impact on us.
  • Any additional commercialized products or any future products that obtain regulatory clearance, authorization, approval, accreditation or licensure will remain subject to regulatory scrutiny and our failure to maintain our regulatory clearances, authorizations, approvals, accreditations or licensures could adversely affect our reputation, business and results of operations.
  • If any of our diagnostic products or services cause or contribute to a death or serious injury, or malfunction in certain ways, we will be required to report such death, serious injury or malfunction under applicable medical device reporting regulations, and such events can result in voluntary corrective actions or agency enforcement actions.
  • We are subject to various laws and regulations, such as healthcare fraud and abuse laws, false claim laws and health information privacy and security laws, among others, and failure to comply with these laws and regulations may have an adverse effect on our business.
  • We will need to increase the size of our organization.
  • Risks Related to Our Common Stock
  • Our common stock is a “penny stock,” which may make it more difficult for investors to sell their shares of common stock due to suitability requirements.
  • Our common stock is currently traded on the OTC QB Market, which may have an unfavorable impact on our stock price and liquidity.
  • Financial Industry Regulatory Authority (“FINRA”) sales practice requirements may also limit a stockholder’s ability to buy and sell our common stock, which could depress the price of our common stock.
  • Since our common stock is currently quoted on the OTC QB Markets our stockholders may face significant restrictions on the resale of our common stock due to state “blue sky” laws and the sale of common stock in this offering is subject to state “blue sky” laws.
  • If we fail to comply with the rules under the Sarbanes-Oxley Act of 2002 related to accounting controls and procedures in the future, or, if we discover additional material weaknesses and other deficiencies in our internal control and accounting procedures, our stock price could decline significantly and raising capital could be more difficult.
  • The market price of our common stock may be volatile and adversely affected by several factors.
  • U.S. federal income tax reform could adversely affect us.
  • Certain provisions in our certificate of incorporation and by-laws, and of Delaware law, may prevent or delay an acquisition of our company, which could decrease the trading price of our common stock.
  • Future sales and issuances of our common stock or rights to purchase common stock pursuant to our equity incentive plan could result in additional dilution of the percentage ownership of our stockholders and could cause our share price to fall.
  • We may be at risk of securities class action litigation.
  • If securities or industry analysts do not publish research or reports about our business, or if they change their recommendations regarding our stock adversely, our stock price and trading volume could decline.
  • We presently do not intend to pay cash dividends on our common stock.

Legal proceedings

From time to time, we may become a party to various legal actions and complaints arising in the ordinary course of business. In addition to commitments and obligations in the ordinary course of business, we are subject to various claims, pending and potential legal actions for damages, investigations relating to governmental laws and regulations and other matters arising out of the normal conduct of our business. It is possible that cash flows or results of operations could be materially affected in any particular period by the unfavorable resolution of one or more of these contingencies.

The opening of Item 3, Legal Proceedings.4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70